Key result
Early IV beta-blockers reduce recurrent ischemia and ventricular arrhythmias in AMI but risk cardiogenic shock.
Why the study?
Does early intravenous beta-blockers reduce recurrent ischaemia and ventricular arrhythmia in patients with acute myocardial infarction?
Does early intravenous beta-blockers reduce recurrent ischaemia and ventricular arrhythmia in patients with acute myocardial infarction?
Early intravenous beta-blockers in acute myocardial infarction reduce recurrent ischemia and arrhythmias but increase the risk of cardiogenic shock, highlighting the need for careful patient selection.
Early intravenous beta-blockers reduce the risk of recurrent ischaemia and ventricular arrhythmia in the treatment of acute myocardial infarction. These beneficial efficacy, however, are balanced by a high rate of cardiogenic shock. It has great significance for reliable identification of subgroups of patients among whom treatment is really advantageous. The present article is a review on the efficacy and safety of the early intravenous beta-blockers, and provides an evaluation procedure to guide clinicians applying intravenous beta-blockers to clinical practice.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2017) conducted a review in Acute Myocardial Infarction. Early intravenous beta-blockers was evaluated. Early intravenous beta-blockers reduce recurrent ischaemia and ventricular arrhythmia in acute myocardial infarction but are associated with a high rate of cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: